Recordati SpAMEX:RECN 71 Days Inventory is 245.86 as of Mar. 2026, which is 18% above its 10-year median of 207.51. GuruFocus rates MEX:RECN with a GF Score™ of 71/100 and a GF Value™ of MXN1,150.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 919 Drug Manufacturers companies, Recordati SpA ranks worse than 71.82% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Recordati SpA's Average Total Inventories for the
three
months ended in Mar. 2026 was MXN11,380 Mil. Recordati SpA's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN4,224 Mil.
Hence, Recordati SpA's Days Inventory for the
three
months ended in Mar. 2026 was 245.86.
The historical rank and industry rank for Recordati SpA's Days Inventory or its related term are showing as below:
MEX:RECN'
s Days Inventory Range Over the Past 10 Years
Min: 152.64 Med: 207.51 Max: 231.25
Current: 231.25
During the past 13 years, Recordati SpA's highest Days Inventory was 231.25. The lowest was 152.64. And the median was 207.51.
MEX:RECN's Days Inventory is ranked worse than 71.82% of 919
companies
in the Drug Manufacturers industry
Industry Median: 162.44
vs MEX:RECN: 231.25
Recordati SpA's Days Inventory
increased
from Mar. 2025 (203.85) to Mar. 2026 (245.86).
It might indicate that Recordati SpA's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Recordati SpA's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.37.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Recordati SpA's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.77.
Recordati SpA (MEX:RECN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Recordati SpA's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Recordati SpA's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Recordati SpA Days Inventory Related Terms
Recordati SpA Days Inventory Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RECN vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Days Inventory distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MEX:RECN) has a Days Inventory of 245.86 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Recordati SpA and its competitors. This is 18% above median its historical median of 207.51. Over the past decade, Recordati SpA's Days Inventory has ranged from 152.64 to 231.25. According to the industry distribution chart, Recordati SpA ranks #660 out of 919 companies in the Drug Manufacturers industry, placing it in the top 71.8%.
Is Recordati SpA's Days Inventory too high?
Recordati SpA's current Days Inventory of 245.86 is 18% above median its 10-year median of 207.51. Over the past 10 years, this metric has ranged from a low of 152.64 to a high of 231.25. The Drug Manufacturers industry median Days Inventory is 162.44. Recordati SpA's value of 245.86 is 51.4% above this industry median. Based on the distribution chart, Recordati SpA ranks #660 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #660 out of 919 companies for Days Inventory. This places Recordati SpA in the lower half of its industry. The industry median Days Inventory is 162.44. Recordati SpA's value of 245.86 is 51.4% above this benchmark. Historically, Recordati SpA's own Days Inventory has ranged from 152.64 to 231.25 over the past decade. While the company's 10-year median is 207.51 vs. the industry median of 162.44, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 162.44, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Days Inventory of 245.86 is 51.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 162.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Days Inventory is 245.86, which is 18% above median its own 10-year median of 207.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MEX:RECN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,150.22, compared to a current price of MXN1,019.79 — trading 11.3% below its estimated fair value. The current Days Inventory is 245.86, which is 18% above median its 10-year median of 207.51 and 51.4% above the Drug Manufacturers industry median of 162.44. Recordati SpA's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Recordati SpA (MEX:RECN), the current Days Inventory is 245.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MEX:RECN) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of MXN1,019.79 is trading 11.3% below its estimated GF Value™ of MXN1,150.22.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MEX:RECN:
Days Inventory: 245.86 (18% above median its 10-year median of 207.51)
GF Value™: MXN1,150.22 vs. price of MXN1,019.79 (11.3% below fair value)
Industry Position: 51.4% above the Drug Manufacturers median (#660 of 919)
No single metric tells the full story. See the MEX:RECN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
71GF Score
Get the complete analysis for MEX:RECN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RECN has been successfully added to your 
